Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 1.00 |
| ▸ | CASP7 | P55210 | 11/20 | 0.67 |
| ▸ | CASP9 | P55211 | 4/20 | 0.67 |
| ▸ | CASP1 | P29466 | 7/20 | 0.66 |
| ▸ | CASP2 | P42575 | 3/20 | 0.57 |
| ▸ | CASP6 | P55212 | 3/20 | 0.57 |
| ▸ | CASP4 | P49662 | 2/20 | 0.57 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092156 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535370 | 0.89 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535374 | 0.89 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6536379 | 0.88 | CASP3 (0.78) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535574 | 0.86 | CASP3 (0.76) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535570 | 0.86 | CASP3 (0.76) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535354 | 0.85 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL7484695 | 0.83 | CASP3 (0.71) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535351 | 0.81 | CASP3 (0.68) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535352 | 0.81 | CASP3 (0.68) | CASP3CASP7CASP9CASP1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-09-25 | — | — | US | claimed |
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | claimed |
| US-8871718-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-8470782-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-8153593-B2 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-11-24 | — | — | US | disclosed |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; AND THE WASHINGTON UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-7579313-B2 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-02-12 | — | — | US | disclosed |
| EP-1931205-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-02-21 | — | — | US | disclosed |
| US-7265093-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007025247-A2 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-03-09 | — | — | US | disclosed |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | disclosed |
| US-6403792-B1 | INHIBIT PRODUCTION OF CASPASE 3 AND 7 IN MAMMALS | SMITHKLINE BEECHAM CORPORATION | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044401-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | CASP3 647/4885CASP7 691/4885CASP9 725/4885 |
| US-20090042806-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | CASP3 3728/4885CASP7 3210/4885CASP9 3496/4885 |
| US-20080233102-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | CASP3 647/4885CASP7 691/4885CASP9 725/4885 |
| US-20130102633-A1 | TRANSGLUTAMINASE INHIBITORS AND METHODS OF USE THEREOF | TGM2, TGM3, TGM1 | CASP3 3728/4885CASP7 3210/4885CASP9 3496/4885 |
| US-20110286995-A1 | Drug Therapy for Celiac Sprue | SI, DNPEP, SPINT2 | CASP3 647/4885CASP7 691/4885CASP9 725/4885 |
| US-20060052308-A1 | Administering to a patient an effective dose of [(S)-1-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-methyl-carbamoyl]-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid benzyl ester; treatment of glioblastoma, meningioma, melanoma and colon cancer | MGMT, GMFG, HNMT | CASP3 1380/4885CASP7 919/4885CASP9 1849/4885 |
| US-20040167069-A1 | Drug therapy for Celiac Sprue | SI, DNPEP, SPINT2 | CASP3 647/4885CASP7 691/4885CASP9 725/4885 |
| US-20090312272-A1 | Transglutaminase inhibitors and methods of use thereof | TGM2, TGM3, TGM1 | CASP3 3728/4885CASP7 3210/4885CASP9 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.